Targeting IRF4 may be worth investigating further regarding its potential to overcome the chemoresistance of BCL2‐overexpressing DLBCL to standard therapies (see Graphical Abstract). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.